LATEST NEWS IN PROSTATE CANCER
XTANDI® (ENZALUTAMIDE) APPROVED BY U.S. FDA FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).